Entrada Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed September 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 21/100
What the filing says
MPM BioVentures 2014 and 2018 funds, managed by Ansbert Gadicke, Luke Evnin, and Todd Foley, sold approximately 217,000 shares of Entrada Therapeutics common stock between 08/24/26 and 09/09/26 at prices ranging from $6.76 to $7.70 per share, averaging ~$7.17. Total sale value approximately $1.6M. This is a standard portfolio rebalancing disclosure; no change in holdings structure or control.
Why this rating
Sales ~0.84% of $191M market cap; routine fund rebalancing without control change or strategic shift.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.